Search
Now showing items 151-160 of 169
Characterising transcriptomic and immune heterogeneity in aggressive invasive lobular breast cancers
(Institute of Cancer Research (University Of London), 2024-01-16)
Invasive Lobular Carcinoma (ILC) is the second most common histological subtype of breast cancer (BC) accounting for 10-15% of all BCs. It is a unique disease entity with distinct histological appearances, molecular ...
Deciphering evolutionary trajectories in hereditary renal cell carcinomas
(Institute of Cancer Research (University Of London), 2024-01-16)
Establishing the limits of predictability in cancer evolution has significant implications for
precision medicine. Clear cell renal cell carcinoma (ccRCC) follows highly deterministic
evolutionary pattern with conserved ...
The response of the Eukaryotic replisome to DNA quadruplex structures
(Institute of Cancer Research (University Of London), 2024-01-18)
Sequences that can form DNA secondary structures, such as G-quadruplexes (G4s) and intercalated-Motifs (iMs), are abundant in the human genome and play a range of physiological roles. However, they can pose a challenge to ...
Improving tumour target coverage in spine stereotactic radiotherapy
(Institute of Cancer Research (University Of London), 2024-01-16)
Spine stereotactic body radiotherapy (SBRT) has high rates of local control. Local
control failure rates are higher in cases with epidural disease and radioresistant
histologies. A limiting factor is the proximity of the ...
Identification of biomarkers to predict differential response to therapeutic agents in advanced triple negative breast cancer
(Institute of Cancer Research (University Of London), 2024-01-16)
Patients with triple negative breast cancer (TNBC) tend to have poor outcomes compared to other subtypes, and this is historically due to a lack of targeted therapies for these patients. PARP inhibitors have recently been ...
Immunogenic cell death in cancer therapy
(Institute of Cancer Research (University Of London), 2024-01-16)
Triple negative breast cancer (TNBC) is a heterogenous disease which carries a poor prognosis, with the worst outcomes in the basal-like subtype. Despite the introduction of immunotherapy in the treatment paradigm the ...
Elucidating Prostate Cancer Immunopathology and Immunogenomics Utilizing Computational Analyses of Digital Imaging
(Institute of Cancer Research (University Of London), 2024-01-05)
Prostate Cancer (PCa) is a prominent non-cutaneous malignancy in men in developed countries, necessitating effective treatments. Chronic inflammation is a key factor in PCa pathogenesis and progression, involving a ...
Identification and characterisation of drug-tolerant persister cells arising in response to targeted CHK1 inhibition
(Institute of Cancer Research (University Of London), 2024-01-05)
Drug-tolerant persisters (DTPs) are a subpopulation of slow-cycling cells that have been identified in several cancer cell lines following lethal exposure to targeted and cytotoxic therapeutics and shown to precede acquisition ...
Deconstructing the soft tissue sarcoma matrisome and adhesome for drug target and biomarker discovery
(Institute of Cancer Research (University Of London), 2023-12-08)
Soft tissue sarcomas (STS) are a rare and diverse group of mesenchymal malignancies that present significant challenges in clinical management due to their extensive clinical and biological heterogeneity. STS have a dismal ...
Lysine-targeting covalent inhibitors
(Institute of Cancer Research (University Of London), 2023-12-14)
Targeted Covalent Inhibitors (TCIs) represent an increasingly important strategy in modern drug discovery. TCIs exploit high affinity, reversible ligands which are then modified with modestly-reactive electrophilic warheads ...